Sign Out
TIVICAY must not be administered concurrently with medicinal products with narrow therapeutic windows, that are substrates of organic cation transporter 2 (OCT2), including but not limited to dofetilide, pilsicainide or fampridine (also known as dalfampridine; see Interactions).
TIVICAY is contraindicated in patients with known hypersensitivity to dolutegravir or to any of the excipients.
Continue with Google